Resveratrol

Stilbenoid: SIRT1 ↑, NF-κB/apoptosis mod; moderate adjunct in breast/prostate/colorectal/lung.

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Early human studies plus extensive preclinical data; definitive oncology RCTs remain limited.RSVTrans-resveratrol3,5,4'-Trihydroxy-trans-stilbene

Forms: Micronized capsules (250-500 mg trans-resveratrol) · Liposomal or cyclodextrin-complexed for bioavailability

Educational only, not medical advice. OncoForge makes no claim that Resveratrol treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Pleiotropic polyphenol that activates SIRT1, suppresses NF-κB–driven inflammation, and promotes apoptosis; adjunct potential with mixed but encouraging human signals.

Evidence at a glance

Tier 2 · animalBreastProstateColorectalLung

Preclinical SIRT/NF-κB dominance; phase II PSA signals in prostate; meta-QoL modest; ongoing combos in CRC/breast; bioavailability hurdle noted.

How it may work

Resveratrol (RSV) activates SIRT1→FOXO/PGC-1α deacetylation, enhancing DNA repair/mitochondrial efficiency and reducing senescence signaling. It inhibits NF-κB (IKK/p65), lowering COX-2/IL-6/TNF and angiogenic VEGF. RSV primes intrinsic apoptosis (Bax↑/Bcl-2↓, caspase-3/9) and can modulate ER/AR signaling in hormone-responsive tumors. Synergistic effects with chemo/radiation are reported preclinically and in small trials.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Sirtuin↑SIRT1 activation for DNA repair/mitochondria
NF-κB↓IKK/p65 inhibition, cytokine reduction
Apoptosis↑Bax/Bcl-2 modulation, caspase activation
VEGF↓Anti-angiogenic effects
ER/ARModHormone signaling modulation

SirtuinNF-κBApoptosis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Doxorubicin: Improved response in breast cancer.
Curcumin: NF-κB dual-hit in colorectal.
Quercetin: Apoptosis synergy in prostate.
EGCG: SIRT1 amplification in lung models.

Overlapping mechanisms

Sirtuin: Overlaps pterostilbene; no additive gain.
NF-κB ↓: Redundant with curcumin; monitor inflammation.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi UpsetEstrogenicDrug Interactions

Potential interactions

anticoagulantsMonitorModerateTheoreticalPotential platelet inhibition.
CYP3A4 substratesMonitorLowTheoreticalInduction may lower levels (e.g., statins).
DoxorubicinSynergizeLowTheoreticalApoptosis enhancement in breast.

Timing

With-meal: Improves tolerance.
BID: Divided for steady levels.

References

Research

No published studies for Resveratrol yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Resveratrol depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 250–1000 mg/day (po) divided BID; micronized for absorption, Adjunct 500 mg/day; up to 1 g for preclinical extrapolation; trans-isomer preferred; cycle if GI issues..

Trials studying Resveratrol

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Appears in these protocol claims

Resveratrol is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.

Fasting-Mimicking Diet / Ketogenic / Press-Pulse Claims : Metabolic approaches focused on glucose, insulin, ketones, fasting stress, and treatment sensitivity.

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar